Selective extracorporeal blood disinfection systems and related methods are disclosed. The systems comprise an input tube forming a flowpath for the flow of infected blood. The systems further comprise a disinfection unit comprising a microbicidal light emitting device configured to emit visible light within the range of about 380-425 nm and/or about 500-700 nm, and a treatment flowpath in communication with the input tube that is substantially transparent to the emitted light of the microbicidal light emitting device for receiving at least a portion of the flow of the infected blood therethrough. The microbicidal light emitting device effectuates a dose of the emitted light to the infected blood flowing through the treatment flowpath to disinfect the blood. The systems also comprise an output tube in fluid communication with the treatment flowpath forming a flowpath for the flow of the disinfected blood from the disinfection unit.

A system and a method facilitate the extracorporeal inactivation of pathogens of blood products. The system includes an input peristaltic pump, at least one apheresis device, at least one plasma-treating system, and an output peristaltic pump. The input peristaltic pump, the apheresis device, the plasma-treating system, and the output peristaltic pump are in fluid communication with each other. The plasma-treating system includes at least one primary ultraviolet light (UVL) device, at least one heating device, and at least one cooling device. The input peristaltic pump facilitates the flow of blood from a patient through the system. The apheresis device facilitates separating of plasma from one or more blood cells. The plasma-treating system heats the plasma, inactivates pathogens within the plasma, and then cools the plasma. The output peristaltic pump facilitates the flow of blood from the system and back to the patient.

System and methods are provided for treating a patient that include a delivery device sized for introduction into a target site within a patient's body, a source of one or more therapeutic and/or diagnostic agents coupled to the delivery device, and a tubular member sized for introduction into the patient's vasculature to isolate the thoracic duct. Once the thoracic duct is isolated, fluid may be removed from the thoracic duct, e.g., to prevent the agents that transit from the target site into the thoracic duct from entering the patient's vasculature, and/or to modulate flow through the thoracic duct to modulate concentration and/or resident time of the agents at the target site. The one or more agents may include particles sized for preferential transit into the lymphatic system.

Provided are methods for preparing pathogen-inactivated platelet compositions, as well as processing sets and compositions related thereto.

A method is provided for calibrating a pump during a blood separation procedure that has at least a first and second state or phase where fluid is flowed to or from a reservoir by action of the pump. The state or phase of the procedure may be a priming state, a draw state, a separation state and a return state, and the pump calibration may be performed between consecutive performances of the same procedure state. The calibration is based on a variance between the volume of fluid predicted to be processed by the pump for the given state of the procedure and the actual volume processed based on the change of weight of the reservoir. Recalibration of the pump, if necessary, is accomplished before the performance of the second phase is commenced.

A system for separating a suspension of biological cells is disclosed comprising a single-use fluid circuit and a durable hardware component. The fluid circuit comprises a separator having a housing that includes an inlet for introducing the suspension of biological cells into the gap, a first outlet in communication with the gap for flowing a first type of cells from the separator, and a second outlet in communication with the second side of the filter membrane for flowing a second type of cells from the separator. The hardware component comprises a pump for flowing the suspension of biological cells to the inlet of the separator and at least one flow control device associated with the first outlet and the second outlet of the separator for selectively opening and closing the outlets so as to permit one of the first type of cells and the second type of cells to flow out of the separator in accordance with a predetermined duty cycle equal to the ratio of a target flow rate of first type of cells through the first outlet to the predetermined inlet flow rate.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

The present disclosure relates to a blood treatment apparatus having of each at least one control device; one user interface; one receiving section for releasably receiving an organizer, wherein the organizer comprises components releasably connected thereto for the extracorporeal blood treatment options, in particular dialysis method being executable by the blood treatment apparatus, wherein the blood treatment apparatus comprises in particular in the area of its reception section or in the area corresponding thereto a device for the releasable fastening or fixing of the organizer (on)to the blood treatment apparatus and/or at least a device for acting on components of an organizer which is releasably received in or on the receiving section. Furthermore, an organizer is specified.

Blood separation systems and methods are provided for separating blood under conditions of reduced plasma clarity. The system may assess plasma clarity by monitoring light transmissivity of plasma or comparing an actual plasma flow rate to an ideal plasma flow rate, with a low flow rate indicating decreased clarity, which may be addressed by increasing the plasma flow rate. For extracorporeal photopheresis, plasma clarity may be a factor in determining the dosage of irradiating light to apply to mononuclear cells. A fluid processing assembly for mononuclear cell collection may include visual indicium, which an operator may use to determine when to end mononuclear cell collection. The system may detect red blood cells flowing toward a mononuclear cell collection container and reverse the direction of flow to prevent red blood cells from entering the container. An operator may also be enabled to selectively begin and/or end harvesting of mononuclear cells.

Disclosed is a polymer for capturing or separating leukocytes. The polymer is prepared by a polymerization reaction of monomers containing an amino and a hydroxyl. The monomer containing an amino and a hydroxyl has the structure of formula (1): ##STR00001##
In formula (1), R1 is independently selected from the group consisting of a hydrogen, a methyl, an ethyl, a hydroxyl, any one of C1 to C12 long carbon chains, and a benzene ring, R2 is independently selected from the group consisting of a hydrogen, a methyl, an ethyl, any one of from C1 to C6 long carbon chains, an amino and a benzene ring, and n is an integer of 1 to 5.